78
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Knowledge and Awareness of HPV Vaccine and Acceptability to Vaccinate in Sub-Saharan Africa: A Systematic Review

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          We assessed the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and acceptability to vaccinate in sub-Saharan African (SSA) countries. We further identified countries that fulfill the two GAVI Alliance eligibility criteria to support nationwide HPV vaccination.

          Methods

          We conducted a systematic review of peer-reviewed studies on the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and acceptability to vaccinate. Trends in Diphtheria-tetanus-pertussis (DTP3) vaccine coverage in SSA countries from 1990–2011 were extracted from the World Health Organization database.

          Findings

          The review revealed high levels of willingness and acceptability of HPV vaccine but low levels of knowledge and awareness of cervical cancer, HPV or HPV vaccine. We identified only six countries to have met the two GAVI Alliance requirements for supporting introduction of HPV vaccine: 1) the ability to deliver multi-dose vaccines for no less than 50% of the target vaccination cohort in an average size district, and 2) achieving over 70% coverage of DTP3 vaccine nationally. From 2008 through 2011 all SSA countries, with the exception of Mauritania and Nigeria, have reached or maintained DTP3 coverage at 70% or above.

          Conclusion

          There is an urgent need for more education to inform the public about HPV, HPV vaccine, and cervical cancer, particularly to key demographics, (adolescents, parents and healthcare professionals), to leverage high levels of willingness and acceptability of HPV vaccine towards successful implementation of HPV vaccination programs. There is unpreparedness in most SSA countries to roll out national HPV vaccination as per the GAVI Alliance eligibility criteria for supporting introduction of the vaccine. In countries that have met 70% DTP3 coverage, pilot programs need to be rolled out to identify the best practice and strategies for delivering HPV vaccines to adolescents and also to qualify for GAVI Alliance support.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities

          Emmanuela Gakidou and colleagues find that coverage of cervical cancer screening in developing countries is on average 19% compared to 63% in developed countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cervical cancer: the sub-Saharan African perspective.

            Cervical cancer is the second most common cancer in women worldwide and the leading cause of cancer deaths in developing countries. While incidence and mortality rates of cervical cancer have fallen significantly in developed countries, 83% of all new cases that occur annually and 85% of all deaths from the disease occur in developing countries. Cervical cancer is the most common cancer among women in sub-Saharan Africa. The incidence is on the increase in some countries. Knowledge and awareness of this disease on the continent are very poor and mortality still very high. Facilities for the prevention and treatment of cervical cancer are still very inadequate in many countries in the region. Governments in sub-Saharan Africa must recognise cervical cancer as a major public health concern and allocate appropriate resources for its prevention and treatment, and for research. Indeed, cervical cancer in this region must be accorded the same priority as HIV, malaria, tuberculosis and childhood immunisations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Achieving high coverage in Rwanda's national human papillomavirus vaccination programme

              PROBLEM: Virtually all women who have cervical cancer are infected with the human papillomavirus (HPV). Of the 275 000 women who die from cervical cancer every year, 88% live in developing countries. Two vaccines against the HPV have been approved. However, vaccine implementation in low-income countries tends to lag behind implementation in high-income countries by 15 to 20 years. APPROACH: In 2011, Rwanda's Ministry of Health partnered with Merck to offer the Gardasil HPV vaccine to all girls of appropriate age. The Ministry formed a "public-private community partnership" to ensure effective and equitable delivery. LOCAL SETTING: Thanks to a strong national focus on health systems strengthening, more than 90% of all Rwandan infants aged 12-23 months receive all basic immunizations recommended by the World Health Organization. RELEVANT CHANGES: In 2011, Rwanda's HPV vaccination programme achieved 93.23% coverage after the first three-dose course of vaccination among girls in grade six. This was made possible through school-based vaccination and community involvement in identifying girls absent from or not enrolled in school. A nationwide sensitization campaign preceded delivery of the first dose. LESSONS LEARNT: Through a series of innovative partnerships, Rwanda reduced the historical two-decade gap in vaccine introduction between high- and low-income countries to just five years. High coverage rates were achieved due to a delivery strategy that built on Rwanda's strong vaccination system and human resources framework. Following the GAVI Alliance's decision to begin financing HPV vaccination, Rwanda's example should motivate other countries to explore universal HPV vaccine coverage, although implementation must be tailored to the local context.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                11 March 2014
                : 9
                : 3
                : e90912
                Affiliations
                [1 ]Pathfinder International, Watertown, Massachusetts, United States of America
                [2 ]Northeastern University, Boston, Massachusetts, United States of America
                [3 ]Countway Library of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
                [4 ]Cameroon Baptist Convention Health Services, Bamenda, Cameroon
                [5 ]University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
                Universidad Nacional de La Plata, Argentina
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: JGO SP RW PAB EW TW. Analyzed the data: JGO SP. Wrote the paper: JGO SP RW PAB EW TW.

                Article
                PONE-D-13-50210
                10.1371/journal.pone.0090912
                3949716
                24618636
                4168825a-e82f-4d06-b958-52f96e290806
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 28 November 2013
                : 4 February 2014
                Page count
                Pages: 16
                Funding
                The authors have no support or funding to report.
                Categories
                Research Article
                Medicine
                Clinical Immunology
                Immunity
                Vaccination
                Vaccines
                Clinical Research Design
                Systematic Reviews
                Infectious Diseases
                Viral Diseases
                Human Papillomavirus Infection
                Non-Clinical Medicine
                Health Care Policy
                Health Education and Awareness
                Oncology
                Cancer Risk Factors
                Viral and Bacterial Causes of Cancer
                Cancers and Neoplasms
                Gynecological Tumors
                Cervical Cancer

                Uncategorized
                Uncategorized

                Comments

                Comment on this article